Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA drug, device postmarket programs to be audited by GAO at Rep. Wyden's request.

Executive Summary

FDA DRUG, DEVICE POSTMARKET SURVEILLANCE PROGRAMS TO BE EXAMINED BY GAO at the request of Rep. Wyden (D-Ore.). General Accounting Office staffers say an initial meeting on the audit with personnel from the agency's device and drug centers is scheduled for the week of May 1. In an April 12 letter, Wyden asks GAO "to assess the scope and adequacy" of FDA's device and drug post-market surveillance programs. The study also is to include "an examination of the extent to which FDA is able to monitor other countries' experience with newly approved pharmaceuticals, and translate that information into findings and appropriate actions protecting U.S. consumers."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS026122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel